deltatrials
Completed PHASE1/PHASE2 NCT01120925

Autologous Bone Marrow Derived Stem Cells in Decompensate Cirrhotic Patients

Comparison of Therapeutic Outcome of Twice Transplantation of CD133+ and MNC BM Derived Stem Cells in Cirrhotic Patients: Clinical Trial, Double Blind, Phase I/II

Sponsor: Royan Institute

Conditions Liver Cirrhosis
Interventions CD133 Control MNC
Updated 6 times since 2017 Last updated: Apr 24, 2014 Started: May 31, 2010 Primary completion: Jul 31, 2013 Completion: Jul 31, 2013

Listed as NCT01120925, this PHASE1/PHASE2 trial focuses on Liver Cirrhosis and remains completed. Sponsored by Royan Institute, it has been updated 6 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Change History

6 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1_PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE1_PHASE2

    First recorded

May 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Royan Institute
  • University of Tehran
Data source: Royan Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Tehran, Iran